PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang Z, Zhang Y, Chen X, Guo S, Lei Y, Xu Y, Ji C, Bi Z, Wang K. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. Cancer Biology & Therapy. 2015;16(4):511–517. doi:10.1080/15384047.2015.1017691.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S and others. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587(2–3):194–205. doi:10.1016/S0925-4439(02)00082-0.
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G and others. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. doi:10.1016/S1470-2045(14)70330-4.
   PubMed Web of Science ®Google Scholar
• Pons S, Asano T, Glasheen E, Miralpeix M, Zhang Y, Fisher TL, Myers MG, Jr., Sun XJ, White MF. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol 1995;15(8):4453–65. doi:10.1128/MCB.15.8.4453.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D and others. Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res. 2007;13(18 Pt 1):5314–21. doi:10.1158/1078-0432.CCR-06-2660.
   PubMed Web of Science ®Google Scholar
• Zhou J, Chen GB, Tang YC, Sinha RA, Wu Y, Yap CS, Wang G, Hu J, Xia X, Tan P and others. Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library. BMC Med Genomics. 2012;5:34. doi:10.1186/1755-8794-5-34.
   PubMed Web of Science ®Google Scholar
• Hu J, Xia X, Cheng A, Wang G, Luo X, Reed MF, Fojo T, Oetting A, Gong J, Yen PM. A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Mol Cancer Ther. 2008;7(12):3719–28. doi:10.1158/1535-7163.MCT-08-0499.
   PubMed Web of Science ®Google Scholar
• Xia X, Cheng A, Akinmade D, Hamburger AW. The N-Terminal 24 Amino Acids of the p55 Gamma Regulatory Subunit of Phosphoinositide 3-Kinase Binds Rb and Induces Cell Cycle Arrest. Mol Cell Biol. 2003;23(5):1717–1725. doi:10.1128/MCB.23.5.1717-1725.2003.
   PubMed Web of Science ®Google Scholar
• Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev. 2009;29(6):903–53. doi:10.1002/med.20159.
   PubMed Web of Science ®Google Scholar
• Elamin YY, Rafee S, Osman N, KJ OB, Gately K. Thymidine Phosphorylase in Cancer; Enemy or Friend? Cancer Microenviron. 2016;9(1):33–43. doi:10.1007/s12307-015-0173-y.
   PubMed Web of Science ®Google Scholar
• Kobashi N, Matsumoto H, Zhao S, Meike S, Okumura Y, Abe T, Akizawa H, Ohkura K, Nishijima K, Tamaki N and others. The Thymidine Phosphorylase Imaging Agent 123I-IIMU Predicts the Efficacy of Capecitabine. J Nucl Med. 2016;57(8):1276–81. doi:10.2967/jnumed.115.165811.
   PubMed Web of Science ®Google Scholar
• Wang G, Yang X, Li C, Cao X, Luo X, Hu J. PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer. Mol Cancer Ther. 2014;13(7):1837–47. doi:10.1158/1535-7163.MCT-14-0049.
   PubMed Web of Science ®Google Scholar
• Wang G, Chen C, Yang R, Cao X, Lai S, Luo X, Feng Y, Xia X, Gong J, Hu J. p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-kappaB pathway. Angiogenesis. 2013;16(3):561–73. doi:10.1007/s10456-013-9336-y.
   PubMed Web of Science ®Google Scholar
• Wang G, Cao X, Lai S, Luo X, Feng Y, Xia X, Yen PM, Gong J, Hu J. PI3K stimulates DNA synthesis and cell-cycle progression via its p55PIK regulatory subunit interaction with PCNA. Mol Cancer Ther. 2013;12(10):2100–9. doi:10.1158/1535-7163.MCT-12-0920.
   PubMed Web of Science ®Google Scholar
• Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016;8(1):57–84. doi:10.1177/1758834015614530.
   PubMed Web of Science ®Google Scholar
• Li X, Wang S, Ren H, Ma J, Sun X, Li N, Liu C, Huang K, Xu M, Ming L. Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy. Cancer Biology & Therapy. 2016;17(6):684–692. doi:10.1080/15384047.2016.1187551.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26. doi:10.1038/nrc3599.
   PubMed Web of Science ®Google Scholar
• Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9–22. doi:10.1016/j.ctrv.2016.08.001.
   PubMed Web of Science ®Google Scholar
• Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R and others. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget. 2016;7(7):7715–31. doi:10.18632/oncotarget.6802.
   PubMedGoogle Scholar
• Daniele G, Gallo M, Piccirillo MC, Giordano P, D'Alessio A, Del Giudice A, La Porta ML, Perrone F, Normanno N, De Luca A. Pharmacokinetic evaluation of capecitabine in breast cancer. Expert Opin Drug Metab Toxicol. 2013;9(2):225–35. doi:10.1517/17425255.2013.759939.
   PubMed Web of Science ®Google Scholar
• Chen CC, Chen LC, Liang Y, Tsang NM, Chang YS. Epstein-Barr virus latent membrane protein 1 induces the chemotherapeutic target, thymidine phosphorylase, via NF-kappaB and p38 MAPK pathways. Cell Signal. 2010;22(7):1132–42. doi:10.1016/j.cellsig.2010.03.008.
   PubMed Web of Science ®Google Scholar
• Ogawa M, Watanabe M, Mitsuyama Y, Anan T, Ohkuma M, Kobayashi T, Eto K, Yanaga K. Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer. Oncol Lett. 2014;8(6):2463–2468.
   PubMed Web of Science ®Google Scholar
• Shigeta K, Ishii Y, Hasegawa H, Okabayashi K, Kitagawa Y. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. World J Surg. 2014;38(12):3248–56. doi:10.1007/s00268-014-2738-1.
   PubMed Web of Science ®Google Scholar
• Acharya N, Yoon JH, Gali H, Unk I, Haracska L, Johnson RE, Hurwitz J, Prakash L, Prakash S. Roles of PCNA-binding and ubiquitin-binding domains in human DNA polymerase eta in translesion DNA synthesis. Proc Natl Acad Sci U S A. 2008;105(46):17724–9. doi:10.1073/pnas.0809844105.
   PubMed Web of Science ®Google Scholar